Drugs / Comvax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00984295 | Jun 2000 → Oct 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00441012 Comparator | Dec 2006 → Jun 2008 | haemophilus infectious disease, hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Comvax | “The mpHBV-Hib was compared with the licensed bivalent HBV-Hib vaccine Comvax™ for immunogenicity and safety.” PMID 21875633 ↗ Aug 2011 |
| Modality | Vaccine | “licensed bivalent HBV-Hib vaccine Comvax™” PMID 21875633 ↗ Aug 2011 |
| Route | Intramuscular | “intramuscular injection” NCT00984295 ↗ |